Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson’s disease

Qin, Jing; Wu, Mingmin; Yu, Shu; Gao, Xingchun; Zhang, Jingjing; Dong, Xingyue; Ji, Jinyan; Zhang, Yuxi; Zhou, Lin; Zhang, Qi; Ding, Fei

doi:10.1016/j.toxlet.2015.08.011

Cited by 34 publications

(19 citation statements)

References 52 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Western blotting was performed according to a protocol used in other reports (Zhai et al ., ; Qin et al ., ; Liu et al ., , ,b; Han et al ., ; Huang et al ., ; Zhang et al ., ; Wang et al ., , ). Primary antibodies against PPARα (ab8934, 1:500; Abcam, Cambridge, UK), BDNF (sc‐20981, 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and GAPDH (2118S, 1:2000; Cell Signaling, Danvers, MA, USA) were used.…”

Section: Methodsmentioning

confidence: 99%

Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice

Song

Wang

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice

Song

Wang

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…However, rotenone can cross the brain barrier by penetrating the cell membrane and acting as a potent inhibitor of mitochondrial complex I leading to cell death. It has been tested in several cellular models that PQQ added to different concentrations in the presence of rotenone, protects the cells from damage and delays their harmful effects (Qin et al, 2015).…”

Section: The Antiproliferative Effects Of Pqqmentioning

confidence: 99%

An Innovative Quinone (Pyrroloquinoline Quinone) and its Antiproliferative Effects

-Encarnación¹,

M.1²,

I.1³

et al. 2019

IJCRR

View full text Add to dashboard Cite

The pyrroloquinoline quinine is a cofactor discovered in bacteria. It is associated with various bacterial soluble and membrane enzymes that directly oxidize sugars, alcohols, aldehydes. In higher organisms, it has been reported that pyrroloquinoline quinine acts as a potent free radical scavenger and it seems to intervene in different processes causing remarkable benefits. One of the most important effects is that pyrroloquinoline quinine induced apoptosis in different cancer cell lines. It is interesting to observe the role of pyrroloquinoline quinine as pro-apoptotic agent. This review shows the most relevant aspects of this cofactor and its antiproliferative effects.

show abstract

“…If we take the term 'natural substrate' to mean a substance to which an organism has been exposed and for which a transporter has a particularly high k cat or k cat /K m , it is reasonable to refer to such a molecule as a 'natural substrate', as in the ergothioneine/SLC22A4 example above. Another exogenous molecule that seems similarly valuable to mammals [93][94][95][96][97][98][99][100][101][102][103][104] and other organisms [105], albeit its uptake transporter is not yet known, is pyrroloquinoline quinone (PQQ) [106], also known as methoxatin, a redox cofactor normally associated with prokaryotes [107; 108].…”

Section: Some Mammalian Transporters With Known Selectivity For Exogementioning

confidence: 99%

Consensus rank orderings of molecular fingerprints illustrate the ‘most genuine’ similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter substrates

O’Hagan

Kell

2017

Preprint

View full text Add to dashboard Cite

We compare several molecular fingerprint encodings for marketed, small molecule drugs, and assess how their rank order varies with the fingerprint in terms of the Tanimoto similarity to the most similar endogenous human metabolite as taken from Recon2. For the great majority of drugs, the rank order varies very greatly depending on the encoding used, and also somewhat when the Tanimoto similarity (TS) is replaced by the Tversky similarity. However, for a subset of such drugs, amounting to some 10% of the set and a Tanimoto similarity of ~0.8 or greater, the similarity coefficient is relatively robust to the encoding used. This leads to a metric that, while arbitrary, suggests that a Tanimoto similarity of 0.75-0.8 or greater genuinely does imply a considerable structural similarity of two molecules in the drug-endogenite space. Although comparatively few (<10% of) marketed drugs are, in this sense, robustly similar to an endogenite, there is often at least one encoding with which they are genuinely similar (e.g. TS > 0.75). This is referred to as the Take Your Pick Improved Cheminformatic Analytical Likeness or TYPICAL encoding, and on this basis some 66% of drugs are within a TS of 0.75 to an endogenite.We next explicitly recognise that natural evolution will have selected for the ability to transport dietary substances, including plant, animal and microbial 'secondary' metabolites, that are of benefit to the host. These should also be explored in terms of their closeness to marketed drugs. We thus compared the TS of marketed drugs with the contents of various databases of natural products. When this is done, we find that some 80% of marketed drugs are within a TS of 0.7 to a natural product, even using just the MACCS encoding. For patterned and TYPICAL encodings, 80% and 98% of drugs are within a TS of 0.8 to (an endogenite or) an exogenous natural product. This implies strongly that it is these exogeneous (dietary and medicinal) natural products that are more to be seen as the 'natural' substrates of drug transporters (as is recognised, for instance, for the solute carrier SLC22A4 and ergothioneine). This novel analysis casts an entirely different light on the kinds of natural molecules that are to be seen as most like marketed drugs, and hence potential transporter substrates, and further suggests that a renewed exploitation of natural products as drug scaffolds would be amply rewarded.

show abstract

Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson’s disease

Cited by 34 publications

References 52 publications

Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice

Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice

An Innovative Quinone (Pyrroloquinoline Quinone) and its Antiproliferative Effects

Consensus rank orderings of molecular fingerprints illustrate the ‘most genuine’ similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter substrates

Contact Info

Product

Resources

About